Provided by Tiger Trade Technology Pte. Ltd.

Ultragenyx Pharmaceutical

15.22
+0.47003.19%
Post-market: 15.05-0.1700-1.12%19:54 EDT
Volume:3.88M
Turnover:58.72M
Market Cap:1.50B
PE:-2.61
High:15.28
Open:14.90
Low:14.67
Close:14.75
52wk High:39.89
52wk Low:12.73
Shares:98.32M
Float Shares:80.72M
Volume Ratio:0.82
T/O Rate:4.81%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-5.8279
EPS(LYR):-5.8316
ROE:-608.47%
ROA:-24.22%
PB:-5.14
PE(LYR):-2.61

Loading ...

Ultragenyx Pharmaceutical - Receives FDA Approval for Rebisufligene Etisparvovec on Sept 17, 2026

THOMSON REUTERS
·
Yesterday

Ultragenyx Pharmaceutical - Announces Ema Validation of Maa for Rebisufligene Etisparvovec Gene Therapy

THOMSON REUTERS
·
Yesterday

Ultragenyx Says EMA Validates MAA for MPS IIIA Gene Therapy Rebisufligene Etisparvovec

Reuters
·
Yesterday

Ultragenyx call volume above normal and directionally bullish

TIPRANKS
·
Sep 24

Movement Alert|Ultragenyx Pharmaceutical Rises 9.39% in Regular Trading, FDA Approval of Fayuvi Gene Therapy Continues to Fuel Rally

Market Focus
·
Sep 23

Ultragenyx Pharma is Maintained at Overweight by Barclays

Dow Jones
·
Sep 21

Ultragenyx price target raised to $35 from $32 at Barclays

TIPRANKS
·
Sep 21

Analysts Offer Insights on Healthcare Companies: Merck & Company (MRK), Envista Holdings (NVST) and Ultragenyx Pharmaceutical (RARE)

TIPRANKS
·
Sep 21

Ultragenyx price target raised to $20 from $18 at Morgan Stanley

TIPRANKS
·
Sep 18

U.S. Stocks on the MOVE-CoreWeave, StubHub, Ultragenyx

Reuters
·
Sep 18

Morgan Stanley Sticks to Its Hold Rating for Ultragenyx Pharmaceutical (RARE)

TIPRANKS
·
Sep 18

Leerink Partners Keeps Their Buy Rating on Ultragenyx Pharmaceutical (RARE)

TIPRANKS
·
Sep 18

Abeona Therapeutics ‘congratulated’ Ultragenyx on U.S FDA approval of UX111

TIPRANKS
·
Sep 18

Ultragenyx price target raised to $39 from $37 at Canaccord

TIPRANKS
·
Sep 18

Ultragenyx Pharma Price Target Raised to $39.00/Share from $33.00 by Cantor Fitzgerald

Dow Jones
·
Sep 18

Stocks to Watch: Xenon Pharmaceuticals, Ultragenyx Pharmaceutical, BRT Apartments

Dow Jones
·
Sep 18

Ultragenyx Pharmaceutical Exec Says U.S. Per Patient Wholesale Acquisition Cost for Fayuvi is Set at $3.95 Million - Conf Call

THOMSON REUTERS
·
Sep 18

Ultragenyx confirms FDA approval of Fayuvi

TIPRANKS
·
Sep 18

Ultragenyx Stock Jumps on Landmark FDA Approval

Dow Jones
·
Sep 18

Ultragenyx Pharmaceutical Rises After FDA Approves Fayuvi for Sanfilippo Syndrome Type A

Dow Jones
·
Sep 18